The FDA approved label updates for Bristol Myers Squibb's therapies, noting the company's development and marketing of CAR T cell therapies.

The entities involved

• FDA →
  • Generic medicine services are seeking approval for launch from the FDA.Mon 17:49
  • A company is seeking FDA feedback on its NEO212 program, with a meeting scheduled at the FDA's White Oak campus.Mon 14:56
• CAR →
  • CAR partnered with the Hospital of the University of Pennsylvania to form Noventra Oncology Alliance, announcing the joint venture headquarters in Philadelphia.Mon 06:18
  • Atlanticus Holdings Corporation completed the sale of its entire Auto Finance segment.Thu 10:20
• Bristol-Myers Squibb →

  American pharmaceutical company

  • Bristol-Myers Squibb is developing innovative treatments and supporting Cyprus' national effort in haematology.Mon 13:45
  • FDA gave tentative approval to Lupin for an alternative formulation of a Bristol-Myers Squibb drug, which Lupin plans to manufacture in Somerset.Mon 09:09

Related events

• FDA is currently reviewing cell therapy products like Breyanzi®, seeking approval for CAR-T cell therapies, but noted insufficient information to establish a link.Sep 4
• Baylor College of Medicine researchers participated in a study on CAR T-cell therapy, co-authored by Andras Heczey.Sep 21
• BioXcel Therapeutics received FDA approval for its drug and announced results from New Haven.Jun 7
• Bristol-Myers Squibb holds exclusive commercial rights in Japan after the FDA accepted Zenas's Biologics License Application.Wed 13:05
• FDA approval enables commercial opportunity involving CBRE Group.Sep 17